Sandbox:Preeti: Difference between revisions

Jump to navigation Jump to search
No edit summary
Ssharfaei (talk | contribs)
No edit summary
Line 5: Line 5:
{| class="wikitable"
{| class="wikitable"
|+
|+
! colspan="2" rowspan="2" |
!Category
! rowspan="2" |Pathophysiology
!Disease
! rowspan="2" |Symptoms
! rowspan="3" |Etiology
! rowspan="2" |Physical  Examination
! colspan="2" rowspan="2" |Mechanism
! colspan="3" |Laboratory Findings
! colspan="12" |Clinical manifestations
! colspan="10" |Laboratory Findings
|-
|-
!
!
! rowspan="2" |Demography
! rowspan="2" |History
! colspan="4" |Symptoms
! colspan="6" |Signs
! colspan="3" |CBC
! rowspan="2" |PBS
! rowspan="2" |LFT
!
!
!Immunochemistry
!Immunochemistry
!Blood work
!Blood work
!Biospy
!Biospy
|-
!
!
!Inherited
!Acquired
!Constitutional b symptoms
!Rash
!Abdominal pain
!Diarrhea
!V/S
!Mass
!LAP
!'''Hepatosplenomegaly'''
!Arthritis
!Other
!WBC
!Hb
!Plt
!
!
!
!
!
|-
|-
|
|
|[[Diffuse large B-cell lymphoma]]]<ref name="Shipp2002">{{cite journal |doi=10.1038/nm0102-68 |pmid=11786909 |title=Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning |journal=Nature Medicine |volume=8 |issue=1 |pages=68–74 |year=2002 |last1=Shipp |first1=Margaret A. |last2=Ross |first2=Ken N. |last3=Tamayo |first3=Pablo |last4=Weng |first4=Andrew P. |last5=Kutok |first5=Jeffery L. |last6=Aguiar |first6=Ricardo C.T. |last7=Gaasenbeek |first7=Michelle |last8=Angelo |first8=Michael |last9=Reich |first9=Michael |last10=Pinkus |first10=Geraldine S. |last11=Ray |first11=Tane S. |last12=Koval |first12=Margaret A. |last13=Last |first13=Kim W. |last14=Norton |first14=Andrew |last15=Lister |first15=T. Andrew |last16=Mesirov |first16=Jill |last17=Neuberg |first17=Donna S. |last18=Lander |first18=Eric S. |last19=Aster |first19=Jon C. |last20=Golub |first20=Todd R. }}</ref><ref name="Rosenwald2002">{{cite journal |doi=10.1056/NEJMoa012914 |pmid=12075054 |title=The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma |journal=New England Journal of Medicine |volume=346 |issue=25 |pages=1937–47 |year=2002 |last1=Rosenwald |first1=Andreas |last2=Wright |first2=George |last3=Chan |first3=Wing C. |last4=Connors |first4=Joseph M. |last5=Campo |first5=Elias |last6=Fisher |first6=Richard I. |last7=Gascoyne |first7=Randy D. |last8=Muller-Hermelink |first8=H. Konrad |last9=Smeland |first9=Erlend B. |last10=Giltnane |first10=Jena M. |last11=Hurt |first11=Elaine M. |last12=Zhao |first12=Hong |last13=Averett |first13=Lauren |last14=Yang |first14=Liming |last15=Wilson |first15=Wyndham H. |last16=Jaffe |first16=Elaine S. |last17=Simon |first17=Richard |last18=Klausner |first18=Richard D. |last19=Powell |first19=John |last20=Duffey |first20=Patricia L. |last21=Longo |first21=Dan L. |last22=Greiner |first22=Timothy C. |last23=Weisenburger |first23=Dennis D. |last24=Sanger |first24=Warren G. |last25=Dave |first25=Bhavana J. |last26=Lynch |first26=James C. |last27=Vose |first27=Julie |last28=Armitage |first28=James O. |last29=Montserrat |first29=Emilio |last30=López-Guillermo |first30=Armando |display-authors=29 }}</ref><ref name="Colomo2003">{{cite journal |doi=10.1182/blood-2002-04-1286 |pmid=12393466 |title=Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma |journal=Blood |volume=101 |issue=1 |pages=78–84 |year=2002 |last1=Colomo |first1=L. |last2=López-Guillermo |first2=A |last3=Perales |first3=M |last4=Rives |first4=S |last5=Martínez |first5=A |last6=Bosch |first6=F |last7=Colomer |first7=D |last8=Falini |first8=B |last9=Montserrat |first9=E |last10=Campo |first10=E }}</ref><ref name="”seer”">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref><ref>Tilly H, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015; 26: v116-v125</ref><ref name="”seer”2">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref><ref name="pmid27271843">{{cite journal| author=Korkolopoulou P, Vassilakopoulos T, Milionis V, Ioannou M| title=Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review. | journal=Adv Anat Pathol | year= 2016 | volume= 23 | issue= 4 | pages= 202-43 | pmid=27271843 | doi=10.1097/PAP.0000000000000117 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27271843  }}</ref>
|[[Diffuse large B-cell lymphoma]]]
|Classified into 2 subtypes based on [[gene expression]] profiles:
|Classified into 2 subtypes based on [[gene expression]] profiles:
*Germinal centre B-cell-like (GCB)
*Germinal centre B-cell-like (GCB)
Line 24: Line 59:
**Cell-cell interactions in immune niches
**Cell-cell interactions in immune niches
**Production and class-switching of immunoglobulins  
**Production and class-switching of immunoglobulins  
|
|
|
|
|
|
* Mass/Lump
* Mass/Lump
Line 36: Line 75:
:  
:  
*
*
|
|
|
|
|
|
* Non tender mass
* Non tender mass


*
*
|
|
|
|
|
|
|
|
|
|
|
|
|
* [[Immunohistochemistry]](IHC)
* [[Immunohistochemistry]](IHC)
Line 73: Line 127:
|
|
* Reciprocal translocation t(14;18)(q32;q21).
* Reciprocal translocation t(14;18)(q32;q21).
|
|
|
|
|
|
*[[Fever]]
*[[Fever]]
Line 84: Line 142:
*[[Dyspnea]]
*[[Dyspnea]]
*Painless swelling in the neck, axilla, groin, thorax and abdomen
*Painless swelling in the neck, axilla, groin, thorax and abdomen
|
|
|
|
|
|
* [[Lymphadenopathy|Central  and peripheral lymphadenopathy]]
* [[Lymphadenopathy|Central  and peripheral lymphadenopathy]]
Line 91: Line 153:


* [[Seizures]]
* [[Seizures]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 102: Line 175:
** The kappa light chain locus on chromosome 2: t(2;8)
** The kappa light chain locus on chromosome 2: t(2;8)
** The lambda light chain locus on chromosome 22: t(8;22)
** The lambda light chain locus on chromosome 22: t(8;22)
|
|
|
|
|
|
* [[Fever]]
* [[Fever]]
Line 107: Line 184:
* Unexplained [[weight loss]]
* Unexplained [[weight loss]]
* [[Swollen lymph nodes]] in the neck, axilla, or groin
* [[Swollen lymph nodes]] in the neck, axilla, or groin
|
|
|
|
|
|
* [[Proptosis]]
* [[Proptosis]]
Line 115: Line 196:


* [[Lymphadenopathy|Peripheral lymphadenopathy]]
* [[Lymphadenopathy|Peripheral lymphadenopathy]]
|
|
|
|
|
|
|
|
|
|
|
|
|
* [[CD19]]
* [[CD19]]
Line 140: Line 232:
* [[Chromosomal translocation]] at '''t(11:14)'''
* [[Chromosomal translocation]] at '''t(11:14)'''
** Over-express [[cyclin D1]]  
** Over-express [[cyclin D1]]  
|
|
|
|
|
|
* Stage IV disease
* Stage IV disease
Line 149: Line 245:
* Weight Loss
* Weight Loss
* Extranodal involvement of gastrointtestinal (GI) tract, lungs, and central nervous system (CNS)
* Extranodal involvement of gastrointtestinal (GI) tract, lungs, and central nervous system (CNS)
|
|
|
|
|
|
* Generalized lymphadenopathy
* Generalized lymphadenopathy
Line 155: Line 255:
* Less commonly
* Less commonly
** Palpable masses in skin, breast, and salivary glands
** Palpable masses in skin, breast, and salivary glands
|
|
|
|
|
|
|
|
|
|
|
|
|
* CD5<sup>+</sup>  
* CD5<sup>+</sup>  
Line 178: Line 289:
** Extranodal marginal zone lymphoma.
** Extranodal marginal zone lymphoma.
* Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40.
* Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40.
|
|
|
|
|
|
* Depends largely on its location
* Depends largely on its location
Line 188: Line 303:
** Hashimoto thyroiditis
** Hashimoto thyroiditis
** Sjögren syndrome.
** Sjögren syndrome.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 202: Line 332:
** Deletion 7q21-32
** Deletion 7q21-32
** Translocations of the CDK6 gene located at 7q21.  
** Translocations of the CDK6 gene located at 7q21.  
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 227: Line 376:
** The ''MEK-ERK'' cascade  
** The ''MEK-ERK'' cascade  
** The ''Phosphatidylinositol 3 kinase (PI3K)-AKT'' cascade
** The ''Phosphatidylinositol 3 kinase (PI3K)-AKT'' cascade
|
|
|
|
|
|
* [[Fever]]
* [[Fever]]
Line 236: Line 389:
* Recurrent [[Infection|infections]]
* Recurrent [[Infection|infections]]
* Early satiety
* Early satiety
|
|
|
|
|
|
* [[Pallor]],
* [[Pallor]],
* [[Petechiae]]
* [[Petechiae]]
* [[Splenomegaly]]
* [[Splenomegaly]]
|
|
|
|
|
|
|
|
|
|
|
|
|
* [[Annexin A1]]  
* [[Annexin A1]]  
Line 262: Line 430:
|-
|-
|[[Multiple myeloma|Plasma cell myeloma]]
|[[Multiple myeloma|Plasma cell myeloma]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 270: Line 457:
|-
|-
|[[Chronic lymphocytic leukemia]] / [[Chronic lymphocytic leukemia|small lymphocytic lymphoma]]
|[[Chronic lymphocytic leukemia]] / [[Chronic lymphocytic leukemia|small lymphocytic lymphoma]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 278: Line 484:
|-
|-
|[[Monoclonal B-cell lymphocytosis]]
|[[Monoclonal B-cell lymphocytosis]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 286: Line 511:
|-
|-
|[[B-cell prolymphocytic leukemia]]
|[[B-cell prolymphocytic leukemia]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 294: Line 538:
|-
|-
|[[Waldenström's macroglobulinemia|Waldenström's macroglubulinemia]]
|[[Waldenström's macroglobulinemia|Waldenström's macroglubulinemia]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 302: Line 565:
|-
|-
|[[Monoclonal gammopathy of undetermined significance]] (MGUS)
|[[Monoclonal gammopathy of undetermined significance]] (MGUS)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 310: Line 592:
|-
|-
|[[Heavy chain disease]]
|[[Heavy chain disease]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 318: Line 619:
|-
|-
|Solitary plasmacytoma of bone
|Solitary plasmacytoma of bone
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 326: Line 646:
|-
|-
|Extraosseous plasmacytoma
|Extraosseous plasmacytoma
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 334: Line 673:
|-
|-
|Monoclonal immunoglobulin deposition diseases
|Monoclonal immunoglobulin deposition diseases
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 342: Line 700:
|-
|-
|Extranodal marginal zone lymphoma of [[MALT lymphoma|mucosa-associated lymphoid tissue]] (MALT lymphoma)
|Extranodal marginal zone lymphoma of [[MALT lymphoma|mucosa-associated lymphoid tissue]] (MALT lymphoma)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 350: Line 727:
|-
|-
|Large B-cell lymphoma with IRF4 rearrangement
|Large B-cell lymphoma with IRF4 rearrangement
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 358: Line 754:
|-
|-
|[[Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle center lymphoma]]
|[[Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle center lymphoma]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 366: Line 781:
|-
|-
|T-cell/histiocyte-rich large B-cell lymphoma
|T-cell/histiocyte-rich large B-cell lymphoma
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 374: Line 808:
|-
|-
|[[Lymphomatoid granulomatosis]]
|[[Lymphomatoid granulomatosis]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 382: Line 835:
|-
|-
|[[Primary mediastinal large B-cell lymphoma|Primary mediastinal (thymic) large B-cell lymphoma]]
|[[Primary mediastinal large B-cell lymphoma|Primary mediastinal (thymic) large B-cell lymphoma]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 390: Line 862:
|-
|-
|[[Intravascular large B-cell lymphoma]]
|[[Intravascular large B-cell lymphoma]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 398: Line 889:
|-
|-
|ALK1 large B-cell lymphoma
|ALK1 large B-cell lymphoma
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 406: Line 916:
|-
|-
|Plasmablastic lymphoma
|Plasmablastic lymphoma
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 414: Line 943:
|-
|-
|[[Primary effusion lymphoma]]
|[[Primary effusion lymphoma]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 422: Line 970:
|-
|-
|High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements
|High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 434: Line 1,001:
* The [[tumor]] [[Cell (biology)|cells]] originate from [[memory T cells]] or [[skin]] homing [[CD4+ T cells]] expressing [[cutaneous]] [[lymphocyte]] [[antigen]] (CLA) and [[chemokine]] [[receptors]] [[CCR4]]<nowiki/>and CCR7.
* The [[tumor]] [[Cell (biology)|cells]] originate from [[memory T cells]] or [[skin]] homing [[CD4+ T cells]] expressing [[cutaneous]] [[lymphocyte]] [[antigen]] (CLA) and [[chemokine]] [[receptors]] [[CCR4]]<nowiki/>and CCR7.
* It is understood that cutaneous t cell lymphoma (maycosis fungoides, Sezary sydrome ) is the result of malignant T cell that derived from a mature CD41 CD45RO1 memory T cells.
* It is understood that cutaneous t cell lymphoma (maycosis fungoides, Sezary sydrome ) is the result of malignant T cell that derived from a mature CD41 CD45RO1 memory T cells.
|
|
|
|
|
|
* [[Epidermis (skin)|Epidermal]] [[atrophy]] or poikiloderma
* [[Epidermis (skin)|Epidermal]] [[atrophy]] or poikiloderma
Line 446: Line 1,017:
* [[Anemia]]
* [[Anemia]]
* May progress to [[Sezary syndrome]] (Skin involvement plus hematogenous dissemination)
* May progress to [[Sezary syndrome]] (Skin involvement plus hematogenous dissemination)
|
|
|
|
|
|
* Cutaneous manifestaions
* Cutaneous manifestaions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 460: Line 1,065:
|
|
|-
|-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 468: Line 1,092:
|
|
|-
|-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 482: Line 1,125:
** Phosphatidylinositol-3 kinase (PI3K),
** Phosphatidylinositol-3 kinase (PI3K),
** Mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK)
** Mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK)
|
|
|
|
|
|
Symptoms of T-cell large granular lymphocyte leukemia may include the following:
Symptoms of T-cell large granular lymphocyte leukemia may include the following:
Line 491: Line 1,138:
* [[Bone pain]]
* [[Bone pain]]
* [[Dyspnea]]
* [[Dyspnea]]
|
|
|
|
|
|
* Usually appear pale and malnourished.
* Usually appear pale and malnourished.
Line 497: Line 1,148:
* [[Hepatomegaly]]
* [[Hepatomegaly]]
* [[Splenomegaly]]
* [[Splenomegaly]]
|
|
|
|
|
|
|
|
|
|
|
|
|
* [[CD3]]+
* [[CD3]]+
Line 513: Line 1,175:
|-
|-
|[[Subcutaneous panniculitis-like T-cell lymphoma]]
|[[Subcutaneous panniculitis-like T-cell lymphoma]]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Line 520: Line 1,201:
|
|
|}
|}
<references />

Revision as of 18:57, 28 December 2018


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]

Category Disease Etiology Mechanism Clinical manifestations Laboratory Findings
Demography History Symptoms Signs CBC PBS LFT Immunochemistry Blood work Biospy
Inherited Acquired Constitutional b symptoms Rash Abdominal pain Diarrhea V/S Mass LAP Hepatosplenomegaly Arthritis Other WBC Hb Plt
Diffuse large B-cell lymphoma] Classified into 2 subtypes based on gene expression profiles:
  • Germinal centre B-cell-like (GCB)
  • Activated B-cell-like (ABC).
    • B cell receptor (BCR) signalling
    • B cell migration/adhesion
    • Cell-cell interactions in immune niches
    • Production and class-switching of immunoglobulins
  • Mass/Lump
  • Rapidly enlarging lymph nodes.
  • Painless
  • May be present in neck, groin or abdomen
  • It is not uncommon to have lymphoma in extranodal sites. B symptoms :
  • Fever
  • Night sweats
  • weight loss
  • Non tender mass
  • Immunohistochemistry(IHC)
    • CD20, CD3, CD5, CD45, CD10, BCL-2, BCl-6, MYC, IRF-4/ MUM-1, Ki-67
  • Flow Cytometry Panel
    • Kappa/ Lambda, CD3, CD5, CD45, CD10, CD19, CD20
  • Cytology (for primary CNS lymphoma only)
  • Genetic testing
    • 8q24/MYC translocations
    • Immunoglobulin genes clonally rearranged and hypermutated
    • Mutation of BCL6, MYC, PAX5, PIM1, RhoH/TTFn, TP53 genes
    • Translocations involving c-MYC, BCL6, and IgH gene.
  • Neutropenia
  • Anemia
  • Hypergammaglobulinemia
  • Screening tests for HCV, HBV and HIV.

Centroblastic

Immunoblastic::

  • > 90% immunoblasts
  • Trapezoid shaped large lymphoid cells with significant basophilic cytoplasm

Anaplastic:

  • Very large cells with a round, oval, or polygonal shape that may resemble Reed-Sternberg cells of Hodgkin's lymphoma or Anaplastic Large cell Lymphoma.
Follicular lymphoma
  • Reciprocal translocation t(14;18)(q32;q21).
Burkitt lymphoma
  • Translocation of chromosome 8 myc locus with 3 possible partners (accounting for 90% of translocations):
    • The Ig heavy chain region on chromosome 14: t(8;14)
    • The kappa light chain locus on chromosome 2: t(2;8)
    • The lambda light chain locus on chromosome 22: t(8;22)
  • Medium-sized (~1.5-2x the size of a RBC) with uniform size ("monotonous") -- key feature (i.e. tumor nuclei size similar to that of histiocytes or endothelial cells)
  • Round nucleus
  • Small nucleoli
  • basophilic cytoplasm
  • Brisk mitotic rate and apoptotic activity
  • Cellular outline usually appears squared off
  • "Starry-sky pattern":
    • The stars in the pattern are tingible-body macrophages (macrophages containing apoptotic tumor cells)
    • The tumour cells are the sky
B cell lymphoma Mantle cell lymphoma
  • Stage IV disease
  • B symptoms,
  • Generalized lymphadenopathy
  • Abdominal distention
  • Fatigue
  • Night sweats
  • Weight Loss
  • Extranodal involvement of gastrointtestinal (GI) tract, lungs, and central nervous system (CNS)
  • Generalized lymphadenopathy
  • Hepato-splenomegaly
  • Mental Retardation
  • Less commonly
    • Palpable masses in skin, breast, and salivary glands
  • CD5+
  • B-cell antigen positive
    • CD19
    • CD20
    • CD22
  • Cyclin D1 is overexpressed.
CBC
  • Anemia and cytopenias are secondary to bone marrow infiltration
  • Lymphocytosis > 4000/µL
  • Elevated LDH
  • Germinal centers filled by small-to-medium atypical lymphocytes.
  • Nodular appearance may be evident from expansion of the mantle zone in 30-50% of patients early in the disease.
Nodal marginal zone B-cell lymphoma
  • Arise from memory B cells. Include
    • Splenic marginal zone lymphoma
    • Nodal marginal zone lymphoma
    • Extranodal marginal zone lymphoma.
  • Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40.
  • Depends largely on its location
  • Gastric marginal zone lymphoma
    • Dyspepsia
    • Abdominal pain
    • Hemorrhage
  • Chronic infectious conditions or autoimmune processes, such as
    • H pylori gastritis
    • Hashimoto thyroiditis
    • Sjögren syndrome.
  • AE1/AE3
  • B-cell markers CD20, CD79a, CD10, CD23, and bcl-2 are expressed
  • Follicular cells in reactive zone
  • Centrocyte like cells in marginal zone lymphoma
Splenic marginal zone lymphoma
  • Clonal rearrangements of the immunoglobulin genes (heavy and light chains) .
    • Deletion 7q21-32
    • Translocations of the CDK6 gene located at 7q21.
  • B-cells replace the normal white pulp of the spleen.
  • The neoplastic cells compromise
  • Sinus invasion
  • Epithelial histocytes
  • Plasmacytic differentiation of neoplastic cells.
  • Splenic Hilar Lymph Nodes
  • Bone Marrow Biopsy
    • Splenic marginal zone lymphoma in bone marrow displays a nodular pattern with morphology similar to what is observed in the splenic hilar lymph nodes.
Hairy cell leukemia
  • Production of cytokines, such as TNF alpha and IL-2R, provide important stimuli for malignant B cells proliferation in hairy cell leukemia.
    • The p38-MAPK-JNK cascade
    • The MEK-ERK cascade
    • The Phosphatidylinositol 3 kinase (PI3K)-AKT cascade
  • Tartrate-resistant acid phosphatase positive
  • CBC
  • Small cells with "fried egg"-like appearance
  • Well-demarcated thread-like cytoplasmic extensions
  • Clear cytoplasm
  • Central round nucleus
  • Peri-nuclear clearing ("water-clear rim" appearance)
Plasma cell myeloma
Chronic lymphocytic leukemia / small lymphocytic lymphoma
Monoclonal B-cell lymphocytosis
B-cell prolymphocytic leukemia
Waldenström's macroglubulinemia
Monoclonal gammopathy of undetermined significance (MGUS)
Heavy chain disease
Solitary plasmacytoma of bone
Extraosseous plasmacytoma
Monoclonal immunoglobulin deposition diseases
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
Large B-cell lymphoma with IRF4 rearrangement
Primary cutaneous follicle center lymphoma
T-cell/histiocyte-rich large B-cell lymphoma
Lymphomatoid granulomatosis
Primary mediastinal (thymic) large B-cell lymphoma
Intravascular large B-cell lymphoma
ALK1 large B-cell lymphoma
Plasmablastic lymphoma
Primary effusion lymphoma
High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements
T cell lymphoma Mycosis fungoides / Sézary syndrome
  • Cutaneous manifestaions
T-cell granular lymphocytic leukemia
  • Disregulation of signaling pathways:
    • FAS/FAS-L
    • Phosphatidylinositol-3 kinase (PI3K),
    • Mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK)

Symptoms of T-cell large granular lymphocyte leukemia may include the following:

  • Neutropenia
  • Anemia
  • Hypergammaglobulinemia
  • Clonal rearrangements of the T-cell receptor (TCR) gene
  • Chronic (> 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood
  • Large granular lymphocyte count greater than 2.0 × 109/L
  • Lymphocytosis (typically 2-20x109/L)
Subcutaneous panniculitis-like T-cell lymphoma